Baxter (NYSE:BAX) shares were up today after the company reported preliminary net sales for the fourth quarter of fiscal 2019 that topped the Wall Street consensus. The Deerfield, Ill.-based company posted net sales of $3 billion for the fourth quarter, marking 7% growth on a reported basis and 9% growth on an operational basis. That number […]
Baxalta
Report: Medtech M&A values up sharply in 1st half of 2016
The cumulative value of mergers & acquisitions in the medical device space jumped nearly 50% during the 1st half of 2016, even as the total number of deals fell at a double-digit clip, according to MergerMarket. There were some 394 deals worth a total of $74.5 billion during H1 2016, according to the report, marking […]
Baxter boosts Baxalta share exchange offer
Baxter (NYSE:BAX) said today that its raising the size of its offer to exchange its own shares for those of its Baxalta (NYSE: BXLT) pharmaceuticals spinout ahead of its acquisition by Shire (NSDQ:SHPGY). Baxter cut its stake in Baxalta in January from 19.4% to 13.8%. In March, Deerfield, Ill.-based Baxter exchanged about 59.4 million Baxalta shares at $39.40 apiece, leave […]
Baxter to further trim stake in Baxalta ahead of $32B Shire buyout
Baxter (NYSE:BAX) plans to further trim its stake in Baxalta (NYSE:BXLT), the biopharm business it spun out last year, reducing its ownership to 5.1% ahead of Baxalta’s $32 billion takeover by Shire (NSDQ:SHPGY). In January, Baxter cut its stake in Baxalta from 19.4% to 13.8%. In the latest move, Deerfield, Ill.-based Baxter will exchange about 59.4 million Baxalta shares […]
Baxalta wants Shire to boost $30B takeover bid
(Reuters) — Baxalta (NYSE:BXLT), the spinout of Baxter‘s (NYSE:BAX) biopharmaceuticals division, wants Shire (NSDQ:SHPGY) to improve on its $30 billion bid significantly before it will engage in talks, while its Dublin-based rival could sweeten its offer if it gets to see the U.S. biotech company’s books, according to sources on both sides. Both camps are pushing hard behind […]
ConMed ripe for M&A | The week in medtech M&A
Analyst: ConMed ripe for M&A spree May 19, 2015 by Fink Densford ConMed, in the middle of an under-appreciated turnaround, could be poised to augment its growth via selective acquisitions, according to Leerink Partners analyst Richard Newitter. Newitter, who upgraded CNMD shares to “outperform” and boosted the price target to $64 from $60, wrote in […]
Baxter looks to growth post-Baxalta spinout
Baxter logs Q1 sales, earnings beats
Baxter biopharm spinout Baxalta’s R&D is Cambridge-bound
